As the world responds to the COVID-19 pandemic, robust evidence in priority populations is urgently needed to guide clinical care and public health policy. However, there are gaps in knowledge regarding the impact of SARS-CoV-2 on pregnant persons and their infants. Moreover, the maternal-newborn population requires unique consideration and care due to increased vulnerability to respiratory infections and to medical interventions used to treat infection. Access to maternal and infant biological samples is therefore imperative for gaining a more comprehensive understanding of the burden of SARS-CoV-2 on a pregnant population.
The Rapid Response Maternal-Infant Clinical and Biospecimen Access Platform, or Biorepository Study, is a project aimed at better understanding the burden of COVID-19 on pregnancy. To do this, we have established a Biorepository of data and samples for future studies related to COVID-19 in pregnant populations.
Recruitment for the Biorepository Study is now closed. For further information, please contact us via email at email@example.com
The Biorepository is associated with CANCOVID-Preg and funded by the UBC Strategic Investment Fund and the Canadian Institutes of Health Research. The Biorepository is also registered with the Canadian Tissue Repository Network (https://biobanking.org/biobanks/view/562)